PerkinElmer and JN Macri Technologies Sign Licensing Agreement to Expand Prenatal Risk Assessment; Agreement Highlights PerkinElmer's Continued Investment in Maternal Health Technologies.

BOSTON -- PerkinElmer Inc. (NYSE: PKI), a world leader in neonatal and prenatal screening, and JN Macri Technologies, LLC have signed a license agreement which gives PerkinElmer rights to manufacture and sell kits for the measurement of free beta human chorionic gonadotrophin (free hCGa) in liquid blood for risk assessment of fetal anomalies during pregnancy.

As a marker of Down's syndrome and other trisomies, free hCGa is an important means of improving the efficacy of risk assessment within the first trimester of pregnancy. The technology covered under the agreement includes reagents used to detect amounts of free hCGa in the blood of pregnant women, and software that utilizes free hCGa measurements to calculate the risk of a fetus having chromosomal abnormalities.

"We are pleased to expand our capabilities in the high growth area of maternal health screening," said Peter B. Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. "With our leading edge screening technologies, early detection programs increase treatment and management options and improve the quality of life."

"Measurement of free hCGa allows for a noninvasive, highly accurate risk assessment during pregnancy," said Dr. J.N. Macri, president and chief executive officer of JN Macri Technologies. "We are pleased that our agreement with PerkinElmer will enable greater market access to this important technology."

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results and plans concerning business development opportunities, are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.